Advertisement
Abstract| Volume 92, SUPPLEMENT 1, S12, March 2018

Soluble immune checkpoints CD27, Lag3, PD-L2 and Tim3 in early stage NSCLC patients

DOI:https://doi.org/10.1016/j.ejca.2018.01.030
Soluble immune checkpoints CD27, Lag3, PD-L2 and Tim3 in early stage NSCLC patients
Previous ArticleTumor-specific neoantigens drive T-cell clonotype convergence
Next ArticleThe influence of stromal cells on CD3+ CD8+ tumor infiltrating lymphocyte subpopulations in cancer microtissues
      Rational: Within the evolving area of immune checkpoint inhibitory therapies predictive biomarkers are still rare and intricate in clinical routine, even though they are highly warranted to improve patient outcome and cost effectiveness.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Publication history

      P02.12

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2018.01.030

      Copyright

      © 2018 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX